Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Cancer
Interventions: High-flow Oxygen, Low-flow Oxygen, High-flow Air, Low-flow Air; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Smoking Cessation
Interventions: Intervention, Enhanced Traditional Care control; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Exposure During Pregnancy
Interventions: Dimethyl fumarate, Peginterferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Asthma, Sleep Apnea
Interventions: Bilevel PAP (4 weeks), Usual Care (4 weeks), Washout Period (4 weeks); Device · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Venglustat, Itraconazole; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Multiple Sclerosis
Interventions: armodafinil; Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Obstructive Sleep Apnea Syndrome
Interventions: Sleep Study, Neurocognitive Testing, CBF During Wakefulness, CBF During Sleep; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 12 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions: High-Touch, High-Tech, Optimal Discharge Planning; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Behavioral Dietary Intervention, Best Practice, Electronic Medical Record, Questionnaire Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Respiratory Syncytial Virus
Interventions: Nirsevimab; Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 0 Days to 12 Months
Enrollment: 49,680 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acute Suicidal Depression (ASD)
Interventions: Subanesthetic dose intravenous ketamine (KET), Electroconvulsive therapy (ECT); Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Baltimore, Maryland • Belmont, Massachusetts + 6 more

Conditions: Lower Limb Spasticity
Interventions: Vibrotactile Stimulation (Static Use), Vibrotactile Stimulation (Dynamic Use), Vibrotactile Stimulation (Neurophysiological Mechanism); Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Adolescent Behavior, Mental Health Issue
Interventions: Navigation Arm, Control Arm; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 4 Years to 12 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Oakland, California • Seattle, Washington

Conditions: Lateral Canthal Lines, Glabellar Lines
Interventions: MT10109L, Placebo; Drug
Lead sponsor: Medy-Tox; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more

Conditions: Pulmonary Embolism, Venous Thrombosis
Interventions: Enteric Coated Aspirin, Warfarin, Rivaroxaban; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 18,883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Ventral Hernia, Ventral Incisional Hernia, Post Operative Pain
Interventions: PT Group, Usual Care; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Masked Hypertension
Interventions: Carvedilol, Amlodipine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Glimepiride, Metformin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 115
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 101 more

Conditions: Blepharitis
Interventions: Azithromycin ophthalmic solution, 1%, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more

Conditions: Neoplasms, Medication Toxicity, Tolerance
Interventions: AMXT 1501, Placebo Oral Tablet; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone; Device · Combination Product
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Empagliflozin, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Waco, Texas

Search by objective public record fields.

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

Patient Navigation and Financial Incentives to Promote Smoking Cessation

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Positive Airway Pressure for the Treatment of Asthma

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

Cerebral Blood Flow and Childhood Obstructive Sleep Apnea

Integrated Care (IC) Models for Patient-Centered Outcomes

Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

Trial to Test the Effectiveness of Vibrotactile Stimulation for Lower Limb Spasticity

Assisted Identification and Navigation of Early Mental Health Symptoms in Children

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery

Mechanism of Masked Hypertension - Intervention

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes